Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, eplaortic and peripheral occlusive artery disease.

Autor: Caputo, M., Mantini, G., Floriani, I., Ciceri, M., Noseda, A., Bonomo, L.
Zdroj: European Heart Journal; 1996, Vol. 17 Issue 9, p1329-1336, 8p
Abstrakt: In order to evaluate the relationship between the presence of atherosclerotic disease, documented by angiography, and the fibrinolytic profile, 262 consecutive patients affected by coronary (n=90), epiaortic (n=60) and peripheral (n=104) artery disease have been included in the study. Twenty-two healthy subjects were used as controls for laboratory parameters determination. All patients were classified on the basis of the presence (S+) or absence (S−) of clinically significant stenosis, according to specific scoring systems. Lipoprotein(a), plasminogen activator inhibitor (PAI-1), tissue plasminogen activator (t-PA) and the PAI-1/t-PA ratio were significantly lower in controls than in coronary, epiaortic and peripheral artery disease patients. However, the levels of these parameters were not statistically different between S+ and S− subjects. These results confirm the association between lipoprotein(a), PAT-1 and t-PA levels and the presence of atherosclerotic disease independently of the arterial districts considered, while they do not appear to be directly linked to the severity of the morphological disease. [ABSTRACT FROM PUBLISHER]
Databáze: Complementary Index